Welcome to our dedicated page for Singular Genomics Systems news (Ticker: OMIC), a resource for investors and traders seeking the latest updates and insights on Singular Genomics Systems stock.
Singular Genomics Systems, Inc. is a pioneering life science technology company headquartered in La Jolla, California. Positioned in the heart of the biotech hub near the Pacific Ocean, Singular Genomics is surrounded by prestigious institutions such as the Salk Institute, Scripps, Sanford Burnham, and UCSD. The company is at the cutting edge of genomics, one of the world's fastest-growing industries, and boasts a dynamic and fast-paced work environment that encourages innovation and results.
Singular Genomics is committed to advancing science and medicine through the development of next-generation sequencing (NGS) and multiomics technologies. Their product portfolio includes the G4 Sequencing Platform and the PX Integrated Solution, each designed to cater to distinct market needs. The G4 Sequencing Platform targets the NGS market, while the PX Integrated Solution focuses on single-cell, spatial analysis, and proteomics markets. These products are applicable in diverse fields such as oncology, immunology, neurology, genetic diseases, infectious diseases, and the human microbiome.
The company also recently introduced the G4X™ Spatial Sequencer, a high-throughput in situ spatial sequencing platform capable of direct RNA sequencing, targeted transcriptomics, proteomics, and fluorescent H&E staining from formalin-fixed, paraffin-embedded (FFPE) tissues. This upgrade to the G4 Sequencing Platform marks Singular Genomics as the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
Singular Genomics prides itself on its strong culture of collaboration and innovation. The company offers competitive benefits, including free gym memberships, a 401k plan, flexible vacation policies, and equity incentives, allowing employees to grow alongside the company. The firm’s mission is to empower researchers and clinicians to advance science and medicine, driving forward the potential of genomics to improve human health.
In recent developments, Singular Genomics' management participated in a panel discussion titled “Emerging Life Science Technologies Across Genomics and Proteomics.” This event highlighted their ongoing commitment to innovation and collaboration within the field. The company continues to make significant strides with the G4X system, which promises unprecedented throughput and capabilities for spatial profiling of tissue, further cementing its role as a leader in genomics technology.
Singular Genomics Systems (Nasdaq: OMIC) announced the shipment of five G4 instruments and preliminary fourth-quarter 2022 revenue of approximately $700,000. The revenue reflects only those instruments meeting recognition criteria. CEO Drew Spaventa emphasized the company’s operational success in Q4 and plans for 2023, focusing on scaling production and expanding the customer base. Full financial results for Q4 and 2022 will be disclosed in March 2023.
Singular Genomics Systems (Nasdaq: OMIC) announced its participation at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, scheduled for January 12, 2023, at 10:30 a.m. PT. The company will showcase its innovative next-generation sequencing and multiomics technologies, aiming to empower researchers and clinicians in advancing science. Investors can access a live and recorded webcast of the presentation via the company’s investor relations website.
Singular Genomics Systems (Nasdaq: OMIC) reported its third quarter 2022 financial results, revealing a net loss of $23.8 million or $0.33 per share, compared to a loss of $17.6 million or $0.25 per share in Q3 2021. Operating expenses rose to $24.7 million from $17.5 million, largely due to an expanded workforce to support growth and the G4 system launch. The company remains on track to ship G4 systems in Q4 2022 and has engaged in partnerships for library prep validation, enhancing customer outreach.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will release its third quarter 2022 financial results on November 7, 2022. A conference call with management is scheduled for 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to discuss these results. The company specializes in next-generation sequencing (NGS) and multiomics technologies, offering the G4 Sequencing Platform, a benchtop sequencer designed for speed and accuracy, along with the development of the PX system for in-situ analysis of RNA and proteins at the single-cell level.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) has updated the time for its presentation at the Inaugural Gilmartin Group Emerging Growth Company Showcase. The presentation is now scheduled for 1:30 p.m. PT on Wednesday, August 31, 2022. Interested parties can register and access a live webcast of the event via a provided link. Singular Genomics is focused on developing next-generation sequencing and multiomics technologies, including the G4 Sequencing Platform, designed to deliver fast and accurate genomic results.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually on August 31, 2022, at 7:30 a.m. PT / 10:30 a.m. ET. The event will feature a presentation by Singular Genomics' management, and interested parties can register for a live webcast. The company specializes in next-generation sequencing (NGS) and multiomics technologies, aiming to empower researchers and clinicians with its G4 Sequencing Platform and developing PX system.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) reported significant advancements and financial results for Q2 2022, highlighting the shipment of the first G4 production system in June 2022. The G4 offers superior power and accuracy for researchers. Operating expenses rose to $24.2 million, primarily due to R&D and workforce expansion, compared to $13.9 million in Q2 2021. However, the net loss decreased to $24 million ($0.34 per share) from $37.5 million ($1.18 per share) year-over-year. The company holds $287.5 million in cash and equivalents as of June 30, 2022, ensuring liquidity for growth initiatives.
Singular Genomics Systems (Nasdaq: OMIC) has announced a rescheduled time for its fireside chat at the UBS Genomics 2.0 and MedTech Innovations Summit. The event will now take place at 8:00 a.m. PT on August 11, 2022. Interested parties can listen to the live and recorded webcast at their investor relations website. Singular Genomics focuses on developing next-generation sequencing and multiomics technologies, with its G4 Sequencing Platform already available and a new PX system in development.
Singular Genomics Systems (Nasdaq: OMIC) announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer and Jeff Bullard as Head of Sales for North America. Dr. Ropp will lead the commercial function for the G4 Sequencing Platform, enhancing the company's executive strength. His prior experience includes senior roles at 10x Genomics and Becton, Dickinson and Company. Jeff Bullard, also from 10x Genomics, brings extensive sales leadership experience. These strategic appointments aim to position Singular Genomics as a leader in next-generation sequencing technology.
Singular Genomics Systems, Inc. (Nasdaq: OMIC) will present at the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2022, in Laguna Beach, California. The company's management will participate in a fireside chat scheduled for 1:00 p.m. PT / 4:00 p.m. ET. Investors can access a live and recorded webcast of the event on the company's investor site. Singular Genomics focuses on advanced next-generation sequencing and multiomics technologies, featuring its G4 Sequencing Platform and the upcoming PX system aimed at single-cell analysis.
FAQ
What is the current stock price of Singular Genomics Systems (OMIC)?
What is the market cap of Singular Genomics Systems (OMIC)?
What does Singular Genomics Systems, Inc. do?
Where is Singular Genomics Systems, Inc. located?
What are some of the key products offered by Singular Genomics?
What is the G4X™ Spatial Sequencer?
What markets do Singular Genomics' products serve?
What are some benefits offered to employees at Singular Genomics?
What recent event did Singular Genomics' management participate in?
How is Singular Genomics contributing to scientific advancements?
What makes the G4X system unique?
Where can investors find more information about Singular Genomics?
